GGrantIndex
← Leaderboards

Amyn Habib

Ut Southwestern Medical Center

$5,683,007
Attributed
$5,683,007
Total exposure
6
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $818.2K · FY200925
$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,683,007 · 5
VA$0 · 1

By mechanism

R01$5,154,887 · 4
K08$528,120 · 1
I01$0 · 1

Top collaborators

No co-investigators on record.

Most similar at Ut Southwestern Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Biological

Research focus

BiologicalPathway InteractionsCellsGliomaMediatingOncogenicSignal TransductionOverexpressionGlioblastomaEpidermal Growth Factor ReceptorResponseResistancePlayMalignant NeoplasmsMutantSignal PathwayEgfr Gene AmplificationMouse ModelEpidermal Growth Factor Receptor ViiiLigandsTumorMutationEffective TherapyReporting

Grant awards (27)

The kinase inhibited RTK forms a scaffold to drive therapeutic resistance in cancer$449,196
R01 · FY2025 · CA · contact PI
Bimodal EGFR signaling in glioblastoma$369,000
R01 · FY2025 · NS · contact PI
Bimodal EGFR signaling in glioblastoma$397,700
R01 · FY2024 · NS · contact PI
The role of Nrf2 in mediating resistance to EGFR inhibition in glioblastoma$356,392
R01 · FY2024 · CA · contact PI
Bimodal EGFR signaling in glioblastoma$413,910
R01 · FY2023 · NS · contact PI
The role of Nrf2 in mediating resistance to EGFR inhibition in glioblastoma$367,647
R01 · FY2023 · CA · contact PI
Bimodal EGFR signaling in glioblastoma$429,910
R01 · FY2022 · NS · contact PI
The role of Nrf2 in mediating resistance to EGFR inhibition in glioblastoma$367,645
R01 · FY2022 · CA · contact PI
The role of Nrf2 in mediating resistance to EGFR inhibition in glioblastoma$377,049
R01 · FY2021 · CA · contact PI
Interactions between inflammatory and oncogenic signaling pathways in GBM$0
I01 · FY2021 · VA · contact PI
The role of Nrf2 in mediating resistance to EGFR inhibition in glioblastoma$386,138
R01 · FY2020 · CA · contact PI
Interactions between inflammatory and oncogenic signaling pathways in GBM$0
I01 · FY2020 · VA · contact PI
Interactions between inflammatory and oncogenic signaling pathways in GBM$0
I01 · FY2019 · VA · contact PI
Interactions between inflammatory and oncogenic signaling pathways in GBM$0
I01 · FY2018 · VA · contact PI
Interactions between inflammatory and oncogenic signaling pathways in GBM$0
I01 · FY2017 · VA · contact PI
Interactions between inflammatory and oncogenic signaling pathways in GBM$0
I01 · FY2016 · VA · contact PI
Interactions between inflammatory and oncogenic signaling pathways in GBM$0
I01 · FY2015 · VA · contact PI
Interactions between inflammatory and oncogenic signaling pathways in GBM$0
I01 · FY2014 · VA · contact PI
A Role for RIP1 in Gliomagenesis$307,720
R01 · FY2012 · NS · contact PI
A Role for RIP1 in Gliomagenesis$307,720
R01 · FY2011 · NS · contact PI
A Role for RIP1 in Gliomagenesis$310,860
R01 · FY2010 · NS · contact PI
A Role for RIP1 in Gliomagenesis$314,000
R01 · FY2009 · NS · contact PI
EGFR MEDIATED APOPTOSIS IN GLIOMAS$70,070
K08 · FY2003 · CA
EGFR MEDIATED APOPTOSIS IN GLIOMAS$61,960
K08 · FY2003 · CA
EGFR MEDIATED APOPTOSIS IN GLIOMAS$132,030
K08 · FY2002 · CA
EGFR MEDIATED APOPTOSIS IN GLIOMAS$132,030
K08 · FY2001 · CA
EGFR MEDIATED APOPTOSIS IN GLIOMAS$132,030
K08 · FY2000 · CA